Our Story



with no confusion.

We feel strongly about the value of early diagnosis that we are innovating over and over again to help deliver it.

Our mission at MARK-B™ platform is to change medical environment by providing affordable and accurate diagnostics in a compact platform designed for use in qualified labs in low volume settings. 


A single,

easy-to-operate platform

Using our proprietary electro-chemistry based technology, we’ve enabled point of care blood testing, so that healthcare professionals can access real-time, lab-quality results within minutes. By putting a lab in their hands, healthcare professionals have the information they need to make treatment decisions sooner, saving precious time. This can help lead to enhanced quality of care for you and your family. 

With these solutions, we continue to impact areas of immediate care, from the intensive care unit to the the emergency room.



Company Found

Oct.  Founded headquarters in Korea



Aug.   Raised $5 million in 'Series A' round



Mar.   ‘MARK-B™ cancer’ Clinical testing and joint research with Seoul National University Bundang Hospital

Jul.  Presented MARK-B™ Technology at AACC(American Association for Clinical Chemistry) in Chicago, USA

Oct.  Raised 16.5 million in 'Series B'


Jan.  'MARK-B™ analyzer' CE certification, 'MARK-B™ CEA' test cartridge CE certification

Jun.  'MARK-B™ COVID-19 Ag S' test cartridge CE certification, ‘Sampinute™ COVID-19 Antigen MIA’, CE certification

Aug. KGMP Certification, 'MARK-B™ COVID-19 Ag S', the export licence issued by MFDS, ‘Sampinute™ COVID-19 Antigen MIA’, the export licence issued by MFDS

OCT. Sampinute COVID-19 MIA, FDA EUA approved

DEC. ISO 13485:2016 Certification, 'MARK-B™ COVID-19 Ag’, CE certification


Jan.  Joined HAX Batch 6 program

Apr.  Signed OEM contract with GreenCross MS for supply of in-vitro diagnostic devices for hospitals

May.  Tech-In-Asia Award Winner <beGlobal Seoul 2015>

Oct.  Winner of Zhongguancun Innoway <2015 Demo The World> in Smart Hardware Sector


Apr.  Signed OEM contract with Philosys Inc. for supply of glucosmeters for hospital use

Jun.  Signed MOU with Busan University to commercialize medical research and infrastructure


Jun.  Signed MOU with Korea University Guro Hospital to develop next-generation immunodiagnostic kit for cancer, myocardial infarction, and chronic disease


Aug.  Signed OEM contract with GenBody Inc. for supply of rapid test readers for arboviruses and drugs of abuse


Nov.  Launched elemark® dual check in Korea



Mar.  Completed a Joint “Cancer Diagnostic Performance Verification Clinical Trial” with Seoul National University Bundang Hospital

Aug.  Launched elemark® dual check 2 in Korea



Jan.  'MARK-B™ COVID-19 Ag', the export licence issued by MFDS


Clinical Laboratory


August, 2019

“Evaluation of MARK-B for Quantitative Measurement of  Three Tumor Markers:

Prostate Specific Antigen, Alpha Fetoprotein, and Carcinoembryonic Antigen” 


Tumor marker assays have played a crucial role for screening cancers and monitoring cancer patients, as they reflect the status and prognosis of patients. Alpha fetoprotein (AFP), prostate specific antigen (PSA), and carcinoembryonic antigen (CEA) are the most commonly used tumor marker proteins. The MARK B™ immunoassay system is a novel platform based on magnetic nanoparticles and electrochemical immunoassay.  read

Analytica Chimica Acta


March, 2019

“MESIA: Magnetic force-assisted electrochemical sandwich immunoassays

for quantification of prostate-specific antigen in human serum” 


We propose a new immunoassay technique, called magnetic-force assisted electrochemical sandwich immunoassay (MESIA), where serum biomarkers can be determined by magnetic actuation and electrochemical detection of gold-coated iron oxide nanoparticles as probes for immunocomplex formation. In MESIA, neither washing buffer nor fluidic parts are necessary, because the formation of immunocomplexes and the removal of unbound probes are controlled by magnetic forces.  read

Biosensors and Bioelectronics 


July, 2018

“Magnetic force assisted electrochemical sensor for the detection of thrombin 

with aptamer-antibody sandwich formation” 


A magnetic force assisted electrochemical aptamer-antibody sandwich assay(MESA) was developed for the detection of thrombin as a model protein in serum samples. The MESA using the formation of sandwich complexes on the electrochemical sensor probe for reaction and the removal of unbound bioconjugates from the sensor surface without washing are controlled by a magnetic field.  read